|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 5
Zeitschriftenartikel
Dreyling, Martin; Andre, Marc; Gökbuget, Nicola; Tilly, Herve; Jerkeman, Mats; Gribben, John; Ferreri, Andres; Morel, Pierre; Stilgenbauer, Stephan; Fox, Christopher; Ribera, Jose Maria; Zweegman, Sonja; Aurer, Igor; Bödür, Csaba; Burkhardt, Birgit; Buske, Christian; Caballero, MariaDollores; Campo, Elias; Chapuy, Björn; Davies, Andrew; Leval, Laurence de; Doorduijn, Jeanette; Federico, Massimo; Gaulard, Philippe; Gay, Francesca; Ghia, Paolo; Gronbaek, Kirsten; Goldschmidt, Hartmut; Kersten, Marie-Jose; Kiesewetter, Barbara; Landman-Parker, Judith; Le Gouill, Steven; Lenz, Georg; Leppä, Sirpa; Lopez-Guillermo, Armando; Macintyre, Elizabeth; Mateos Mantega, Maria Victoria; Moreau, Philippe; Moreno, Carol; Nadel, Bertrand; Okosun, Jessica; Owen, Roger; Pospisilova, Sarka; Pott, Christiane; Robak, Tadeusz; Spina, Michelle; Stamatopoulos, Kostas; Stary, Jan; Tarte, Karin; Tedeschi, Allessandra; Thieblemont, Catherine; Trappe, Ralf Ulrich; Trümper, Lorenz H. und Salles, Gilles
(2022):
The EHA Research Roadmap: Malignant Lymphoid Diseases.
In: Hemasphere, Bd. 6, Nr. 6
[PDF, 2MB]
de Leval, Laurence; Alizadeh, Ash A.; Bergsagel, P. Leif; Campo, Elias; Davies, Andrew; Dogan, Ahmet; Fitzgibbon, Jude; Horwitz, Steven M.; Melnick, Ari M.; Morice, William G.; Morin, Ryan D.; Nadel, Bertrand; Pileri, Stefano A.; Rosenquist, Richard; Rossi, Davide; Salaverria, Itziar; Steidl, Christian; Treon, Steven P.; Zelenetz, Andrew D.; Advani, Ranjana H.; Allen, Carl E.; Ansell, Stephen M.; Chan, Wing C.; Cook, James R.; Cook, Lucy B.; D'Amore, Francesco; Dirnhofer, Stefan; Dreyling, Martin; Dunleavy, Kieron; Feldman, Andrew L.; Fend, Falko; Gaulard, Philippe; Ghia, Paolo; Gribben, John G.; Hermine, Olivier; Hodson, Daniel J.; Hsi, Eric D.; Inghirami, Giorgio; Jaffe, Elaine S.; Karube, Kennosuke; Kataoka, Keisuke; Klapper, Wolfram; Kim, Won Seog; King, Rebecca L.; Ko, Young H.; LaCasce, Ann S.; Lenz, Georg; Martin-Subero, Jose I.; Piris, Miguel A.; Pittaluga, Stefania; Pasqualucci, Laura; Quintanilla-Martinez, Leticia; Rodig, Scott J.; Rosenwald, Andreas; Salles, Gilles A.; San-Miguel, Jesus; Savage, Kerry J.; Sehn, Laurie H.; Semenzato, Gianpietro; Staudt, Louis M.; Swerdlow, Steven H.; Tam, Constantine S.; Trotman, Judith; Vose, Julie M.; Weigert, Oliver; Wilson, Wyndham H.; Winter, Jane N.; Wu, Catherine J.; Zinzani, Pier L.; Zucca, Emanuele; Bagg, Adam und Scott, David W.
(2022):
Genomic profiling for clinical decision making in lymphoid neoplasms.
In: Blood, Bd. 140, Nr. 21: S. 2193-2227
Strefford, Jonathan C.; Nowicka, Malgorzata; Hargreaves, Chantal E.; Burton, Cathy; Davies, Andrew; Ganderton, Rosalind; Hiddemann, Wolfgang; Iriyama, Chisako; Klapper, Wolfram; Latham, Kate V.; Martelli, Maurizio; Mir, Farheen; Parker, Helen; Potter, Kathleen N.; Rose-Zerilli, Matthew J. J.; Sehn, Laurie H.; Trneny, Marek; Vitolo, Umberto; Bolen, Christopher R.; Klein, Christian; Knapp, Andrea; Oestergaard, Mikkel Z. und Cragg, Mark S.
(2021):
Single-nucleotide Fc gamma receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma.
In: Blood Advances, Bd. 5, Nr. 15: S. 2935-2944
Seymour, John F.; Marcus, Robert; Davies, Andrew; Gallop-Evans, Eve; Grigg, Andrew; Haynes, Andrew; Herold, Michael; Illmer, Thomas; Nilsson-Ehle, Herman; Soekler, Martin; Duenzinger, Ulrich; Nielsen, Tina; Launonen, Aino und Hiddemann, Wolfgang
(2019):
Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression.
In: Haematologica, Bd. 104, Nr. 6: S. 1202-1208
Trotman, Judith; Barrington, Sally F.; Belada, David; Meignan, Michel; MacEwan, Robert; Owen, Carolyn; Ptacnik, Vaclav; Rosta, Andras; Fingerle-Rowson, Günter R.; Zhu, Jiawen; Nielsen, Tina; Sahin, Deniz; Hiddemann, Wolfgang; Marcus, Robert E. und Davies, Andrew
(2018):
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial.
In: Lancet Oncology, Bd. 19, Nr. 11: S. 1530-1542